AU2020392087B2 - Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use - Google Patents

Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use

Info

Publication number
AU2020392087B2
AU2020392087B2 AU2020392087A AU2020392087A AU2020392087B2 AU 2020392087 B2 AU2020392087 B2 AU 2020392087B2 AU 2020392087 A AU2020392087 A AU 2020392087A AU 2020392087 A AU2020392087 A AU 2020392087A AU 2020392087 B2 AU2020392087 B2 AU 2020392087B2
Authority
AU
Australia
Prior art keywords
trifluoromethyl
methyl
pyrazol
pyrimidin
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020392087A
Other languages
English (en)
Other versions
AU2020392087A1 (en
Inventor
Jennifer R. Allen
Michela BELTRANI
Matthew P. Bourbeau
Teodora P. DAMYANOVA
Iain Lingard
Ana E. MINATTI
Paolo VINCETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2020392087A1 publication Critical patent/AU2020392087A1/en
Application granted granted Critical
Publication of AU2020392087B2 publication Critical patent/AU2020392087B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020392087A 2019-11-25 2020-11-24 Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use Active AU2020392087B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
US62/939,821 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
AU2020392087A1 AU2020392087A1 (en) 2022-06-09
AU2020392087B2 true AU2020392087B2 (en) 2025-10-23

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020392087A Active AU2020392087B2 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use

Country Status (21)

Country Link
US (3) US11512097B2 (enExample)
EP (1) EP4065223A1 (enExample)
JP (2) JP7254246B2 (enExample)
KR (2) KR20230154292A (enExample)
CN (2) CN114728167B (enExample)
AR (1) AR120556A1 (enExample)
AU (1) AU2020392087B2 (enExample)
BR (1) BR112022010054A2 (enExample)
CA (1) CA3162281A1 (enExample)
CL (2) CL2022001357A1 (enExample)
CO (1) CO2022008690A2 (enExample)
CR (1) CR20220308A (enExample)
IL (1) IL293191B2 (enExample)
JO (1) JOP20220125A1 (enExample)
MX (1) MX2022006281A (enExample)
PE (1) PE20231097A1 (enExample)
PH (1) PH12022551282A1 (enExample)
SA (1) SA522432710B1 (enExample)
TW (2) TWI815061B (enExample)
UY (1) UY38971A (enExample)
WO (1) WO2021108408A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11512097B2 (en) 2019-11-25 2022-11-29 Amgen Inc. Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
WO2024112763A1 (en) 2022-11-23 2024-05-30 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253704A1 (en) * 2008-04-04 2009-10-08 Dmitry Koltun PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
EP0242690B1 (en) 1986-04-07 1993-06-30 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
ES2249302T3 (es) 1999-10-15 2006-04-01 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados.
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
BRPI0519288A2 (pt) 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
WO2007012602A1 (de) 2005-07-27 2007-02-01 Basf Aktiengesellschaft Fungizide 5-methyl-6-phenyl-triazolopyrimidinylamine
CN101228166A (zh) 2005-07-27 2008-07-23 巴斯福股份公司 杀真菌的6-苯基三唑并嘧啶基胺
ATE442370T1 (de) 2005-07-27 2009-09-15 Basf Se Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
MX2009002995A (es) 2006-09-28 2009-04-01 Novartis Ag Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
CN101522676A (zh) 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
EA015688B1 (ru) 2007-01-19 2011-10-31 Басф Се Фунгицидные смеси из анилидов 1-метилпиразол-4-илкарбоновой кислоты и азолопиримидиниламинов
WO2008092836A2 (en) 2007-01-30 2008-08-07 Basf Se Method for improving plant health
US8461077B2 (en) 2007-03-23 2013-06-11 Basf Se Combinations of active substances
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8952012B2 (en) 2012-05-24 2015-02-10 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
AU2015251207B2 (en) 2014-04-23 2019-08-22 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
US20200360381A1 (en) 2017-05-15 2020-11-19 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
WO2019055750A1 (en) 2017-09-15 2019-03-21 Aduro Biotech, Inc. PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF
US11512097B2 (en) 2019-11-25 2022-11-29 Amgen Inc. Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253704A1 (en) * 2008-04-04 2009-10-08 Dmitry Koltun PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists

Also Published As

Publication number Publication date
PH12022551282A1 (en) 2023-11-29
US20230159560A1 (en) 2023-05-25
JP2022549739A (ja) 2022-11-28
IL293191A (en) 2022-07-01
KR102598203B1 (ko) 2023-11-03
US20210221824A1 (en) 2021-07-22
CL2023002486A1 (es) 2024-01-12
CL2022001357A1 (es) 2023-03-10
TWI815061B (zh) 2023-09-11
JP7698676B2 (ja) 2025-06-25
KR20220106159A (ko) 2022-07-28
CA3162281A1 (en) 2021-06-03
US11512097B2 (en) 2022-11-29
JOP20220125A1 (ar) 2023-01-30
KR20230154292A (ko) 2023-11-07
AU2020392087A1 (en) 2022-06-09
TW202409042A (zh) 2024-03-01
CR20220308A (es) 2022-08-04
TWI867822B (zh) 2024-12-21
CN114728167A (zh) 2022-07-08
CN114728167B (zh) 2024-03-19
SA522432710B1 (ar) 2025-05-29
IL293191B1 (en) 2025-05-01
JP7254246B2 (ja) 2023-04-07
IL293191B2 (en) 2025-09-01
JP2023078418A (ja) 2023-06-06
CN118161500A (zh) 2024-06-11
US20210188874A1 (en) 2021-06-24
AR120556A1 (es) 2022-02-23
US12448396B2 (en) 2025-10-21
CO2022008690A2 (es) 2022-06-30
BR112022010054A2 (pt) 2022-08-16
EP4065223A1 (en) 2022-10-05
TW202132317A (zh) 2021-09-01
WO2021108408A1 (en) 2021-06-03
MX2022006281A (es) 2022-06-08
UY38971A (es) 2021-06-30
PE20231097A1 (es) 2023-07-18

Similar Documents

Publication Publication Date Title
US11858941B2 (en) Heterocyclic and heteroaryl compounds for treating Huntington's disease
US12448396B2 (en) Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors
WO2021121397A1 (zh) 取代的炔基杂环化合物
JP5777526B2 (ja) 縮合ピリミジン類
US20230331725A1 (en) Compounds for treating huntington's disease
CN103582638A (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
US12473289B2 (en) Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
CN113880842A (zh) 取代的炔基杂环化合物
EA048401B1 (ru) Гетероциклические соединения в качестве ингибиторов дельта-5-десатуразы и способы применения
HK40107593A (zh) 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
WO2025259929A1 (en) COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2026055477A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2026002087A1 (zh) Myt1激酶抑制剂、其药物组合物及其用途
US20240132509A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)